- Dec 3, 2017
- Reaction score
- Political Leaning
Pre-Clinical Data Shows Cybin’s Novel Analog Could Have Advantages Over Psilocybin
This morning in Miami, Cybin, the first and only psychedelic company with a NYSE listing, provided a live research update on its its proprietary molecule, CYB003. The company says it possesses “multiple advantages” over classic psilocybin molecules.
While psilocybin has shown significant promise as a potential treatment for mental health conditions like major depressive disorder and anxiety, drug development companies in the psychedelic space like Cybin (NYSE: CYBN) (NEO: CYBN) are working on developing molecules that mimic the drug, but lack some of the constraints of magic mushrooms’ main ingredient.
This morning at the first Microdose: Wonderland conference in Miami, Cybin, the first and only psychedelic company with a NYSE listing, provided a research update pertaining to its proprietary drug, CYB003. The company says it possesses “multiple advantages” over classic psilocybin molecules.
Though safe, Cybin suggests that in a clinical context, classic psilocybin has limitations, including a long duration (around six hours), a long onset until effects are felt (about 45 minutes), and high variability from patient to patient.
I don't recall seeing this before. Tis article could have used an editor that knew something about drug chemistry. For instance, psilocybin is a molecule & not plural. It refers to this new drug to have several advantages over natural psilocybin but only describes its chemistry as 'deuterated psilocybin.' Hope I run into more on this as I would think that just substituting deuterium for one or more hydrogen atoms would not have this kind of biological effect.